Product Information
HUMIRA(CF) 40 MG/0.4 ML SYRINGE is a brand product labeled by AbbVie Inc., priced at $3367.1829 per EA under NDC 00074024302. Its NADAC has been published 385 times since May 22, 2019.
Manufacturer
AbbVie Inc.NDC
00074024302
Classification
Brand
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Biologic (BLA)
FDA Application
BLA125057On Market Since
11/23/2015
Price Statistics
The NADAC for HUMIRA(CF) 40 MG/0.4 ML SYRINGE has been published 385 times since May 22, 2019, and over the history we have for it it has risen 32.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3367.1829 per EA |
|---|---|
| All-time high | $3373.3901 (Feb 14, 2024) |
| All-time low | $2520.4882 (Dec 18, 2019) |
| 52-week high | $3368.7459 |
| 52-week low | $3364.7475 |
| Median price | $3360.6718 |
| Average price | $3109.0188 |
| Largest weekly change | +8.0% (Jan 11, 2023) |
| Weeks tracked | 385 |
| Tracking since | May 22, 2019 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AbbVie Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Adalimumab market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of HUMIRA(CF) 40 MG/0.4 ML SYRINGE?
The current National Average Drug Acquisition Cost (NADAC) for HUMIRA(CF) 40 MG/0.4 ML SYRINGE, manufactured by AbbVie Inc., is $3367.1829 per EA (NDC 00074024302), effective Sep 30, 2026.
How has the price of HUMIRA(CF) 40 MG/0.4 ML SYRINGE changed over time?
Over the history we have for it, the NADAC for HUMIRA(CF) 40 MG/0.4 ML SYRINGE has risen 32.6%. It has been tracked across 385 weekly CMS publications since May 22, 2019.
What are the highest and lowest recorded NADAC prices for HUMIRA(CF) 40 MG/0.4 ML SYRINGE?
Since May 22, 2019, the NADAC for HUMIRA(CF) 40 MG/0.4 ML SYRINGE has ranged from a low of $2520.4882 (Dec 18, 2019) to a high of $3373.3901 (Feb 14, 2024), with a median of $3360.6718 per EA.
Are there cheaper alternatives to HUMIRA(CF) 40 MG/0.4 ML SYRINGE?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, HUMIRA(CF) 20 MG/0.2 ML SYRINGE, is $3366.1230 per EA — about 0% below HUMIRA(CF) 40 MG/0.4 ML SYRINGE.
Who manufactures HUMIRA(CF) 40 MG/0.4 ML SYRINGE?
HUMIRA(CF) 40 MG/0.4 ML SYRINGE (NDC 00074024302) is labeled by AbbVie Inc., and CMS classifies it as a brand product.